{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:17:29Z","timestamp":1793049449054,"version":"4.5.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Patients with inflammatory bowel diseases may have higher incidences of non-melanoma skin cancers and non-Hodgkin lymphoma, potentially linked to underlying disease and treatments. This analysis assessed incidence rates of these malignancies in Japanese patients with ulcerative colitis or Crohn\u2019s disease, and their association with thiopurine and\/or anti-tumor necrosis factor-\u03b1 treatment, using data from a nationwide administrative database in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients diagnosed with inflammatory bowel disease without malignancy were identified from the Medical Data Vision database. Incident cases of non-melanoma skin cancers and non-Hodgkin lymphoma diagnosed after prescription of thiopurine and\/or anti-tumor necrosis factor-\u03b1 were identified between April 2008 and January 2018. Age- and sex-adjusted incidence rate ratios were calculated relative to the total treated patient population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 75 673 eligible patients were identified at the index date. Thiopurine prescription with or without anti-tumor necrosis factor-\u03b1 agents increased incidence rate ratios for non-melanoma skin cancers relative to the overall population (3.39 and 4.03, respectively). There were no notable differences in non-Hodgkin lymphoma incidence relative to the total population in any treatment subgroup, regardless of prescription of thiopurine and\/or anti-tumor necrosis factor-\u03b1 (all incidence rate ratios, ~1).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>There is no evidence for an increased incidence of non-Hodgkin lymphoma attributable to thiopurine or anti-tumor necrosis factor-\u03b1 treatment in Japanese patients with inflammatory bowel disease. The impact of racial differences on non-Hodgkin lymphoma incidences should be considered. Thiopurine therapy may be a risk factor for non-melanoma skin cancers in Japanese patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjz204","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T12:10:53Z","timestamp":1576843853000},"page":"617-623","source":"Crossref","is-referenced-by-count":43,"title":["Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis"],"prefix":"10.1093","volume":"14","author":[{"given":"Taku","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Uda","sequence":"first","affiliation":[{"name":"Japan Medical Office, Takeda Pharmaceutical Company Limited, Chuo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Udagawa","sequence":"first","affiliation":[{"name":"Japan Medical Office, Takeda Pharmaceutical Company Limited, Chuo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Hibi","sequence":"first","affiliation":[{"name":"Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,23]]},"reference":[{"key":"2020061904033642900_CIT0001","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00535-018-1439-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease","volume":"53","author":"Matsuoka","year":"2018","journal-title":"J Gastroenterol"},{"key":"2020061904033642900_CIT0002","first-page":"189","article-title":"Guidelines for the management of ulcerative colitis in Japan \u2013 developed through integration of evidence and consensus among experts","volume":"4","author":"Hibi","year":"2010","journal-title":"IBD Res"},{"key":"2020061904033642900_CIT0003","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ord\u00e1s","year":"2012","journal-title":"Lancet"},{"key":"2020061904033642900_CIT0004","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00535-016-1241-x","article-title":"Impact of inflammatory bowel disease on Japanese patients\u2019 quality of life: results of a patient questionnaire survey","volume":"52","author":"Ueno","year":"2017","journal-title":"J Gastroenterol"},{"key":"2020061904033642900_CIT0005","author":"Japanese Ministry of Health, Labour and Welfare","year":"2014"},{"key":"2020061904033642900_CIT0006","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00535-013-0866-2","article-title":"Characteristics of Japanese inflammatory bowel disease susceptibility loci","volume":"49","author":"Arimura","year":"2014","journal-title":"J Gastroenterol"},{"key":"2020061904033642900_CIT0007","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1440-1746.2012.07150.x","article-title":"Inflammatory bowel disease in Asia: a systematic review","volume":"27","author":"Prideaux","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"2020061904033642900_CIT0008","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","article-title":"Epidemiology and risk factors for IBD","volume":"12","author":"Ananthakrishnan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2020061904033642900_CIT0009","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3748\/wjg.v20.i1.31","article-title":"Natural history and long-term clinical course of Crohn\u2019s disease","volume":"20","author":"Freeman","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2020061904033642900_CIT0010","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ags3.12177","article-title":"Recent trends (2016\u20132017) in the treatment of inflammatory bowel disease","volume":"2","author":"Masaki","year":"2018","journal-title":"Ann Gastroenterol Surg"},{"key":"2020061904033642900_CIT0011","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/ibd\/izx065","article-title":"Combination immunosuppression in IBD","volume":"24","author":"Bots","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2020061904033642900_CIT0012","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"2020061904033642900_CIT0013","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"2020061904033642900_CIT0014","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.3748\/wjg.v22.i20.4794","article-title":"Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment","volume":"22","author":"Axelrad","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2020061904033642900_CIT0015","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MOG.0000000000000286","article-title":"Risk of cancer in inflammatory bowel disease: going up, going down, or still the same?","volume":"32","author":"Garg","year":"2016","journal-title":"Curr Opin Gastroenterol"},{"key":"2020061904033642900_CIT0016","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am J Epidemiol"},{"key":"2020061904033642900_CIT0017","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"2020061904033642900_CIT0018","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"2020061904033642900_CIT0019","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"key":"2020061904033642900_CIT0020","author":"World Health Organization International Agency for Research on Cancer","year":"2018"},{"key":"2020061904033642900_CIT0021","author":"World Health Organization International Agency for Research on Cancer","year":"2018"},{"key":"2020061904033642900_CIT0022","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"2020061904033642900_CIT0023","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00535-013-0873-3","article-title":"Hematologic malignancies in the Japanese patients with inflammatory bowel disease","volume":"49","author":"Fukata","year":"2014","journal-title":"J Gastroenterol"},{"key":"2020061904033642900_CIT0024","first-page":"5257","article-title":"Skin cancer concerns in people of color: risk factors and prevention","volume":"17","author":"Gupta","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"2020061904033642900_CIT0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"2020061904033642900_CIT0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5826\/dpc.0702a01","article-title":"Epidemiological trends in skin cancer","volume":"7","author":"Apalla","year":"2017","journal-title":"Dermatol Pract Concept"},{"key":"2020061904033642900_CIT0027","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.gtc.2014.05.010","article-title":"The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease","volume":"43","author":"Dulai","year":"2014","journal-title":"Gastroenterol Clin North Am"},{"key":"2020061904033642900_CIT0028","first-page":"784","article-title":"Risk of lymphoma in inflammatory bowel disease","volume":"5","author":"Siegel","year":"2009","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2020061904033642900_CIT0029","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.crohns.2013.04.006","article-title":"Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III)","volume":"8","author":"Magro","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2020061904033642900_CIT0030","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease","volume":"8","author":"Long","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020061904033642900_CIT0031","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"key":"2020061904033642900_CIT0032","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jdermsci.2018.10.004","article-title":"Nation-wide survey of advanced non-melanoma skin cancers treated at dermatology departments in Japan","volume":"92","author":"Fujisawa","year":"2018","journal-title":"J Dermatol Sci"},{"key":"2020061904033642900_CIT0033","author":"National Cancer Registry","year":"2019"},{"key":"2020061904033642900_CIT0034","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2020061904033642900_CIT0035","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/gut.47.4.514","article-title":"Increased incidence of non-Hodgkin\u2019s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low","volume":"47","author":"Farrell","year":"2000","journal-title":"Gut"},{"key":"2020061904033642900_CIT0036","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/ajg.2013.249","article-title":"Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study","volume":"108","author":"Jess","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2020061904033642900_CIT0037","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/DSS.0000000000000694","article-title":"Prevalence and clinical characteristics of nonmelanoma skin cancers among Hispanic and Asian patients compared with white patients in the United States: a 5-year, single-institution retrospective review","volume":"42","author":"Loh","year":"2016","journal-title":"Dermatol Surg"},{"key":"2020061904033642900_CIT0038","author":"National Cancer Institute","year":"2019"},{"key":"2020061904033642900_CIT0039","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjz204\/32505345\/jjz204.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/5\/617\/33406121\/jjz204.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/5\/617\/33406121\/jjz204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T08:04:02Z","timestamp":1592553842000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/14\/5\/617\/5684917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,23]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,12,23]]},"published-print":{"date-parts":[[2020,6,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz204","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2019,12,23]]}}}